{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:08:46Z","timestamp":1793225326357,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2021]]},"DOI":"10.6061\/clinics\/2021\/e2228","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T10:35:00Z","timestamp":1612175700000},"page":"e2228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-8704","authenticated-orcid":false,"given":"Juliana Goldbaum","family":"Crescente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-3785","authenticated-orcid":false,"given":"Alessandra","family":"Dellavance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-7843","authenticated-orcid":false,"given":"Marcio Augusto","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-3105","authenticated-orcid":false,"given":"Flair Jose","family":"Carrilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-9931","authenticated-orcid":false,"given":"Luis Eduardo Coelho de","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9309-1524","authenticated-orcid":false,"given":"Eduardo Luiz Rachid","family":"Can\u00e7ado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.6061\/clinics\/2021\/e2228_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/gut.38.3.384","article-title":"Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass","volume":"38","author":"Bansi","year":"1996","journal-title":"Gut"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2228_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clinre.2012.07.008","article-title":"Antineutrophil cytoplasmic auto-antibodies (ANCA) in autoimmune hepatitis and primary sclerosing cholangitis","volume":"37","author":"Deniziaut","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2228_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ajcp\/111.4.507","article-title":"International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)","volume":"111","author":"Savige","year":"1999","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2228_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1309\/WAEPADW0K4LPUHFN","article-title":"Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases","volume":"120","author":"Savige","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2228_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1309\/F6L4C48RHFMT4AAU","article-title":"Antigen-specific ANCA ELISAs have different sensitivities for active and treated vasculitis and for nonvasculitic disease","volume":"129","author":"Trevisin","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2228_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112877","article-title":"PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC)","volume":"9","author":"Stinton","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2228_bib7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.510250510","article-title":"Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis","volume":"25","author":"Zauli","year":"1997","journal-title":"Hepatology"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2228_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2228_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2228_bib10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0034-1383732","article-title":"Clinical significance of autoantibodies in primary biliary cirrhosis","volume":"34","author":"Nakamura","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2228_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2307\/2340521","article-title":"On the interpretation of \u03c72 from contingency tables, and the calculation of P","volume":"85","author":"Fisher","year":"1922","journal-title":"J Royal Stat Soc"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2228_bib12","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2228_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02295996","article-title":"Note on the sampling error of the difference between correlated proportions or percentages","volume":"12","author":"McNEMAR","year":"1947","journal-title":"Psychometrika"},{"key":"10.6061\/clinics\/2021\/e2228_bib14","author":"R Core Team"},{"issue":"8","key":"10.6061\/clinics\/2021\/e2228_bib15","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis","volume":"152","author":"Weism\u00fcller","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.6061\/clinics\/2021\/e2228_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/gut.33.5.657","article-title":"Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis","volume":"33","author":"Seibold","year":"1992","journal-title":"Gut"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2228_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0676.1996.tb00700.x","article-title":"Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases","volume":"16","author":"Claise","year":"1996","journal-title":"Liver"},{"issue":"5 Pt 1","key":"10.6061\/clinics\/2021\/e2228_bib18","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/0016-5085(91)70028-V","article-title":"Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis","volume":"100","author":"Duerr","year":"1991","journal-title":"Gastroenterology"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2228_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/ajcp\/99.3.277","article-title":"Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis","volume":"99","author":"Hardarson","year":"1993","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2228_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/liv.13238","article-title":"Antineurophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis","volume":"37","author":"Hov","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2228_bib21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0016-5085(95)90215-5","article-title":"High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis","volume":"108","author":"Targan","year":"1995","journal-title":"Gastroenterology"},{"issue":"9","key":"10.6061\/clinics\/2021\/e2228_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1440-1746.1998.tb00767.x","article-title":"Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease","volume":"13","author":"Frenzer","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2228_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2249.2001.01649.x","article-title":"Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy","volume":"126","author":"Terjung","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2228_bib24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2228_bib25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2228_bib26","first-page":"503","article-title":"Anti-neutrophil cytoplasmic antibodies (ANCA) specific for one or several antigens: useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis","volume":"50","author":"Dobric","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.6061\/clinics\/2021\/e2228_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cca.2013.06.005","article-title":"PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease","volume":"424","author":"Mahler","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"45","key":"10.6061\/clinics\/2021\/e2228_bib28","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.3748\/wjg.14.7012","article-title":"A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody","volume":"14","author":"Xu","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2228_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12016-012-8349-4","article-title":"Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease","volume":"45","author":"Arias-Loste","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2228_bib30","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1515\/cclm-2017-0346","article-title":"PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis","volume":"56","author":"Mahler","year":"2017","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.6061\/clinics\/2021\/e2228_bib31","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/rheumatology\/kex170","article-title":"A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies","volume":"56","author":"Bossuyt","year":"2017","journal-title":"Rheumatology"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2228_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/gut.51.4.609","article-title":"Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism","volume":"51","author":"Bittencourt","year":"2002","journal-title":"Gut"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2228_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11894-018-0620-2","article-title":"The IBD and PSC Phenotypes of PSC-IBD","volume":"20","author":"Ricciuto","year":"2018","journal-title":"Curr Gastroenterol Rep"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222000783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222000783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:59:25Z","timestamp":1761721165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222000783"},"secondary":[{"URL":"https:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322021000100225&lng=en&nrm=iso","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7847259\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/antineutrophil-cytoplasmic-antibody-profiles-differ-according-to-type-of-primary-sclerosing-cholangitis-and-autoimmune-hepatitis\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":33,"alternative-id":["S1807593222000783"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e2228","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e2228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e2228"}}